Immunocore Holdings plc - ADR Stock News

Immunocore Holdings focuses on immunotherapy for oncology, with tebentafusp approved for metastatic uveal melanoma and brenetafusp in advanced trials. IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential acquisition. Growth of tebentafusp sales has slowed, increasing reliance on new projects like brenetafusp, which carries ...

Immunocore Holdings plc (NASDAQ:IMCR ) Q4 2024 Earnings Conference Call February 26, 2024 8:00 AM ET Company Participants Clayton Robertson - Head, IR Bahija Jallal - CEO Travis Coy - CFO and Head, Corporate Development Ralph Torbay - Head, Commercial David Berman - Head, R&D Conference Call Participants Michael Yee - Jefferies Jessica Fye - JPMorgan Tyler Van Buren - TD Cowen Eric Schmidt - Ca...

KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will...

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn.

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME